Back to search
Intermediate Risk Prostate Cancer
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Intermediate Risk Prostate Cancer trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Intermediate Risk Prostate Cancer trials you may qualify forThis prospective single-arm phase II study evaluates the safety, feasibility, quality-of-life effects, PSA kinetics, imaging response, and clinical outcomes of…
In this study the investigators will find out whether the use of a new type of boost approach called irreversible electroporation (IRE) is as effective as the s…
This is a Phase II, single arm, multi-centre, prospective clinical trial evaluating next generation Stereotactic Ablative Radiotherapy (SABR) for low, intermedi…
Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers t…
The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11…
Medico-Economic Randomized Trial comparing Focal HIFU Treatment to Radical Prostatectomy in Patients with Favorable Intermediate Risk Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation th…
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men wh…